Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer

被引：0
|
作者：
Jiang, M. [1 ]
Chai, Y. [1 ]
Liu, J. [2 ]
He, M. [1 ]
Zhang, M. [1 ]
Zhou, S. [1 ]
Xu, B. [3 ]
Li, Q. [2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331P
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [41] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Roberto A. Leon-Ferre
    Tina J. Hieken
    Judy C. Boughey
    Annals of Surgical Oncology, 2021, 28 : 2111 - 2119
  • [42] Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
    Kutlu, Yasin
    Cekin, Ruhper
    Aydin, Sabin Goktas
    Shbair, Abdallah T. M.
    Bilici, Ahmet
    Arici, Serdar
    Oven, Bala Basak
    Acikgoz, Ozgur
    Ozcan, Erkan
    Olmez, Omer Fatih
    Cakir, Asli
    Seker, Mesut
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [43] Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
    Yin, Wenjin
    Wang, Yaohui
    Wu, Ziping
    Ye, Yumei
    Zhou, Liheng
    Xu, Shuguang
    Lin, Yanping
    Du, Yueyao
    Yan, Tingting
    Yang, Fan
    Zhang, Jie
    Liu, Qiang
    Lu, Jinsong
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3677 - 3685
  • [44] Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-positive breast cancer patients
    Sato, A.
    Maeda, Y.
    Matsumoto, A.
    Ikeda, T.
    Jinno, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1409 - S1409
  • [45] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
  • [46] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [47] Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer (BC)
    Ng, Dianna
    Krings, Gregor
    Yau, Christina
    White, Kristie
    Hou, Jie
    Chua, Anthony
    Grenert, James P.
    Chen, Yunn-Yi
    CANCER RESEARCH, 2015, 75
  • [48] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer (NCT02957968)
    Bear, Harry
    Deng, Xiaoyan
    Bandyopadhyay, Dipankar
    Idowu, Michael
    Kmieciak, Maciej
    Williams, Monique
    Archer, Giovanni
    Gwaltney, Lindsey
    Dillon, Patrick
    Flora, Daniel
    Stover, Daniel
    Poklepovic, Andrew
    Hackney, Mary
    Ross, Masey
    Vachhani, Hetal
    Louie, Raphael
    McGuire, Kandace
    Grover, Amelia
    Rahman, Tasnim
    Hendrix, Amber
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Usefulness of neoadjuvant chemotherapy in patients with luminal HER2(-) locally advanced breast cancer
    Kim, H. S.
    ANNALS OF ONCOLOGY, 2017, 28
12345